CHICAGO, IL / ACCESSWIRE / February 20, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that on February 16, 2024, its CEO, Mr. Greg Siokas, acquired a total of 60,000 shares of the Company's common stock in the open market at an average price of $0.8301, for a total consideration of $49,806, demonstrating his strong belief in the Company and unwavering dedication to its continuous development.

As previously announced on December 18, 2023, Mr. Siokas may purchase an aggregate of up to $3 million in common shares of the Company in the open market through December 31, 2024, in accordance with applicable securities laws and other restrictions. The timing and total amount of stock purchases will depend on market conditions, corporate and regulatory requirements, prevailing stock prices and other considerations. Since inception, Mr. Siokas has invested more than $15 million in the Company, including approximately $1 million in 2023.

Reflecting on the purchase, Greg Siokas commented: "Our valuation has sharply declined to what I believe is an unjustifiably low level. Over the past year, we have made significant progress on multiple fronts, including, among others, debt reduction, expansion of our proprietary brands, advancements in R&D, and notably, the acquisitions of companies, properties, and drug licenses. Despite these achievements, we believe that our share price has become markedly disconnected from our fundamental strengths, diversified asset base, and future growth prospects. Cosmos is committed to an ambitious plan, and I am dedicated to doing everything within my power to achieve these objectives and significantly enhance shareholder value."

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Chicago, Illinois, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency, it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, and www.zipdoctor.co.